Clinical Trial Search

Primary: Intervention Feasibility as Measured by Number of Providers Agreeing to Participate — 6 Participants

Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2

Primary: Alteration of Microbiota, Alteration of T Cell Function/Activation — 4; 10; 2; 0 participants

Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants

Primary: Number of Subjects With Lipids Checked (Available Now Through National Laboratory Chain) or That Reported Having Their Lipids Checked by Their 1-week or 3-month Visit…

Primary: RADAI Disease Activity Score — -0.4; 0.1 units on a scale — p=0.04

Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale

Primary: 12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score — 11.4 units on a scale — p=<0.01

Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale

Primary: Number of Participants Diagnosed With Rheumatoid Arthritis Also Found to Have Dry Eye Disease — 275 participants

Primary: Slow Wave Sleep — 82.6; 67.3 Minutes

Primary: Event Rate for a Cardiovascular Composite of Incident Myocardial Infarction, Stroke, or Heart Failure — 10.62; 8.13 Events per 1000 person years

Primary: Change From Baseline in Joint Status Assessed by Radiographic (Roentgen) Progression — 6.9; 24.3; 0.0; 0.3 scores on a scale

Primary: Change in VO2 Max, Maximum Oxygen Uptake in ml/Min/kg is the Standard Index of Cardio-respiratory Fitness — 3.82; -0.44 ml/min/kg — p=0.002

Primary: The Proportion of Subjects Who Are Classified as Having Made an Informed Value Concordant Choice at 2 Weeks — 32; 13 Percentage of subjects

Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec

Primary: Low Synovitis Scores — 1 Participants

Primary: Rate of Medication Adherence — 0.76; 0.79; 0.83 percentage of doses taken — p=0.78

Primary: Evaluation of Disease Duration: Time From Diagnosis to Disease-Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis — 11.7177 Months

Primary: Number of Participants With Level of Education Completed — 01; 15; 86; 59 Participants

Primary: IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells of RA Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA. — 0.700; 1.330; 0.777…

Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 participants

Primary: Hospital Anxiety and Depression Scale (HADS) — 107; 46; 20; 27 participants

Primary: Disease Activity — 3.38; 3.62 score on a scale

Primary: Osteoclast Differentiation Ex-vivo — 8; 12; 11; 5 OC/mm2

Primary: Acceptability of Intervention — 4.45; 3.97 score on a scale

Primary: Physician Global Assessment of Disease Activity — 21; 14; 12; 43 mm

Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score

Primary: Percentage of Participants With American College of Rheumatology 20% (ACR20) Response — 34.4; 33.5; 31.5 percentage of participants

Primary: Disease Activity Score (DAS) 28 — 3.4; 2.8; 3.5; 3.1 composite score